Cargando…

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection

We propose an integrative, mechanistic model that integrates in vitro virology data, pharmacokinetics, and viral response to a combination regimen of a direct-acting antiviral (telaprevir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with genotype 1 chronic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adiwijaya, Bambang S., Kieffer, Tara L., Henshaw, Joshua, Eisenhauer, Karen, Kimko, Holly, Alam, John J., Kauffman, Robert S., Garg, Varun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252270/ https://www.ncbi.nlm.nih.gov/pubmed/22241977 http://dx.doi.org/10.1371/journal.pcbi.1002339

Ejemplares similares

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
por: Adiwijaya, Bambang S., et al.
Publicado: (2010)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection
por: Salama, Iman Ibrahim, et al.
Publicado: (2022)

Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
por: Rosenthal, Elana S., et al.
Publicado: (2016)

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012)

Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C
por: Itakura, Jun, et al.
Publicado: (2020)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Transplantation of Organs from Hepatitis C Virus-Positive Donors under Direct-Acting Antiviral Regimens
por: Zahid, Muhammad Nauman
Publicado: (2022)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Soriano, Vicente, et al.
Publicado: (2022)

Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India
por: Gupta, Varun, et al.
Publicado: (2017)

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
por: Shirahashi, Ryosaku, et al.
Publicado: (2021)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
por: Toyoda, Hidenori
Publicado: (2019)

The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons
por: Richter, Vered, et al.
Publicado: (2022)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
por: Abdulla, Maheeba, et al.
Publicado: (2019)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens
por: Akiyama, Matthew J, et al.
Publicado: (2021)

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders
por: Sharafi, Heidar, et al.
Publicado: (2021)

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2020)

Hepatitis C direct‐acting antiviral outcomes in patients 75 years and older
por: Parmar, Parmvir, et al.
Publicado: (2020)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
por: Ko, Soon Young, et al.
Publicado: (2018)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy
por: Llorens-Revull, Meritxell, et al.
Publicado: (2021)

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study
por: Zanone, Maria M., et al.
Publicado: (2021)

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

2228. Late Viral Relapse After Direct-Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients
por: Angelidakis, Georgios, et al.
Publicado: (2018)

Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus
por: Liu, Dandan, et al.
Publicado: (2019)

Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Characterizing Hepatitis C Virus–Specific CD4(+) T Cells Following Viral‐Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure
por: Hartnell, Felicity, et al.
Publicado: (2020)

The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada
por: Chu, Cherry, et al.
Publicado: (2023)

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam
por: Nguyen, Dung Thanh, et al.
Publicado: (2020)

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
por: Tasavon Gholamhoseini, Mohammad, et al.
Publicado: (2022)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4pka46t06mvlh3a8lulgs5tf3t